DelveInsight's "Anemia Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth understanding of ...

ZYAN1 is an oral small molecule that has been designed to inhibit hypoxia-inducible factor prolyl hydroxylase, and thereby increase the natural production of hemoglobin and RBCs in anemic patients.

This included patients on dialysis, including both hemo- and peritoneal dialysis, and those not on dialysis, regardless of prior anaemia treatment with erythropoiesis-stimulating agents (ESAs ...

Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. *Corresponding Author: Frank S. Lee, Department of Pathology and ...

Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea ...